AMAG Pharmaceuticals (NASDAQ:AMAG) Stock Rating Upgraded by BidaskClub

AMAG Pharmaceuticals (NASDAQ:AMAG) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, June 28th, BidAskClub reports.

Other analysts also recently issued research reports about the company. SunTrust Banks restated a “hold” rating and set a $8.00 price objective on shares of TrueCar in a report on Tuesday, May 14th. Cowen restated a “hold” rating and set a $13.00 price objective on shares of AMAG Pharmaceuticals in a report on Monday, June 24th. Cantor Fitzgerald restated a “buy” rating and set a $8.00 price objective on shares of BioDelivery Sciences International in a report on Thursday, March 14th. Barclays reaffirmed a “hold” rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Finally, Zacks Investment Research raised Hanmi Financial from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $16.92.

Shares of NASDAQ AMAG traded down $0.26 during midday trading on Friday, reaching $8.74. 856,614 shares of the company traded hands, compared to its average volume of 1,308,614. The company has a current ratio of 2.30, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The stock’s 50-day moving average is $9.42. AMAG Pharmaceuticals has a 52 week low of $7.81 and a 52 week high of $26.10. The firm has a market capitalization of $295.15 million, a P/E ratio of -2.25 and a beta of 0.47.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The business had revenue of $75.80 million during the quarter, compared to the consensus estimate of $90.13 million. During the same quarter last year, the firm posted ($1.59) earnings per share. AMAG Pharmaceuticals’s revenue was down 35.4% compared to the same quarter last year. As a group, equities analysts anticipate that AMAG Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

In related news, CEO William K. Heiden bought 10,000 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was purchased at an average price of $10.70 per share, with a total value of $107,000.00. Following the completion of the transaction, the chief executive officer now directly owns 490,056 shares of the company’s stock, valued at $5,243,599.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Armistice Capital, Llc bought 259,016 shares of the firm’s stock in a transaction on Tuesday, June 25th. The shares were bought at an average cost of $8.59 per share, with a total value of $2,224,947.44. The disclosure for this purchase can be found here. In the last three months, insiders purchased 328,016 shares of company stock valued at $2,904,577. 4.90% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in AMAG. Robeco Institutional Asset Management B.V. lifted its holdings in shares of AMAG Pharmaceuticals by 6.4% during the first quarter. Robeco Institutional Asset Management B.V. now owns 1,304,639 shares of the specialty pharmaceutical company’s stock worth $16,803,000 after buying an additional 79,007 shares during the last quarter. Royce & Associates LP lifted its holdings in shares of AMAG Pharmaceuticals by 7.1% during the first quarter. Royce & Associates LP now owns 714,457 shares of the specialty pharmaceutical company’s stock worth $9,202,000 after buying an additional 47,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of AMAG Pharmaceuticals by 0.8% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 703,088 shares of the specialty pharmaceutical company’s stock worth $9,056,000 after buying an additional 5,436 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of AMAG Pharmaceuticals by 25.6% in the first quarter. Acadian Asset Management LLC now owns 682,080 shares of the specialty pharmaceutical company’s stock valued at $8,785,000 after purchasing an additional 139,134 shares in the last quarter. Finally, Great Point Partners LLC acquired a new position in shares of AMAG Pharmaceuticals in the fourth quarter valued at $10,097,000.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Article: What does a market perform rating mean?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.